Biohaven’s pipeline drug BHV-7000 has failed to meet the primary endpoint in a pivotal Phase II/III bipolar trial, sinking ...

Following Pfizer’s acquisition, Biohaven’s valuation skyrocketed under Vlad Coric. Find out why BHVN stock’s growth potential ...

Not content with a $1.2 billion licensing deal for Biohaven Pharma's oral migraine therapy rimegepant, Pfizer has just offered to buy the company outright – for a cool $11.6 billion. Pfizer's ...

Four Colorado physicians are named in a lawsuit settlement involving pharmaceutical company Biohaven, which allegedly paid ...

周二，Deutsche Bank开始对Biohaven Pharmaceutical Holding (NYSE: BHVN )的股票进行跟踪，给予买入评级，目标价为65.00美元。分析师认为，首席执行官Vlad ...

California Attorney General Bonta announced a settlement against Pfizer (PFE)-owned Biohaven Pharmaceutical “for submitting false claims to the Medicaid program and other government healthcare ...

The FDA determined that Novo Nordisk’s obesity and diabetes drugs are no longer in short supply. Elsewhere, Concentra made a ...

The all-or-nothing strategy has landed the ‘pride of the pharmaceutical industry' in a situation that deteriorated rapidly.

subsidiary. Pfizer has agreed to pay $59,746,277.54, plus interest, to resolve allegations that the subsidiary, Biohaven Pharmaceutical Holding Company Ltd. (Biohaven), knowingly submitted or ...

The $59,746,277 settlement resolves a federal court case that Connecticut and 37 other states and Puerto Rico had joined against Biohaven Pharmaceutical Holding Company Ltd., a Pfizer-owned local ...